临床试验/NCT00960882

NCT00960882已完成1 期

Gastric Tolerability and Pharmacokinetics of DMMET-01. Daily Intake for 30 Days, in Normal Alimentation Conditions, in Healthy Volunteers.

Laboratorios Silanes S.A. de C.V.1 个研究点分布在 1 个国家目标入组 12 人开始时间: 2007年6月最近更新: 2018年1月30日

适应症

干预措施

试验速览

阶段: 1 期
状态: 已完成
发起方: Laboratorios Silanes S.A. de C.V.
入组人数: 12
试验地点: 1
主要终点: DMMET-01 Plasmatic concentration

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

The purpose of this study is to determine the gastric tolerability and the pharmacokinetics of a new drug for the treatment of type 2 diabetes, DMMET-01, in healthy volunteers.

研究设计

研究类型: Interventional
分配方式: Na
干预模型: Single Group
主要目的: Treatment
盲法: None

入排标准

年龄范围: 18 Years 至 35 Years（Adult）
性别: All
接受健康志愿者: 是

入选标准

•Mexican healthy subjects with normal clinical laboratory test results and imaging (hematology, blood chemistry, urine test, VDRL, Hepatitis B, HIV, chest radiography and electrocardiogram)

排除标准

•Familiar or personal history of diabetes
•History of drug or alcohol abuse within the 2 years prior to the study
•A smoking habit greater tha 10 cigarettes per day
•Intercurrent disease
•Intercurrent treatment with any drug

研究组 & 干预措施

DMMET-01

Experimental

干预措施: DMMET-01 (Drug)

结局指标

主要结局

DMMET-01 Plasmatic concentration

时间窗: 48 hrs (7.5; 15; 30; 45; 60; 75; 90; 120; 150; 180; 205; 240; 360; 480; 600; 720; 1440 and 2880 min)

次要结局

plasmatic glucose(24 hours (6,12,18 and 24))
glycated hemoglobin(24 hours (0 and 24))
Lanza score(30 days (0 and 30))

研究者

发起方

Laboratorios Silanes S.A. de C.V.

申办方类型

Industry

责任方

Sponsor

研究点 (1)

Loading locations...

相似试验

已完成

1 期

Tolerability and Pharmacokinetics of Metformin and Metformin Extended Release (ER)Healthy

NCT00941239Laboratorios Silanes S.A. de C.V.24

已完成

1 期

Single and Multiple Oral Doses of Dabigatran Etexilate in Healthy Chinese SubjectsHealthy

NCT02171572Boehringer Ingelheim28

招募中

1 期

Safety, Tolerability and Pharmacokinetics of 4-MUST, Tablets, 128 mg (Valenta Pharm JSC) During Single and Multiple Oral Administration in Healthy VolunteersCholecystitis

NCT06315387Valenta Pharm JSC42

已完成

1 期

A Trial of SHR6508 in Secondary HyperparathyroidismSecondary Hyperparathyroidism

NCT05221008Shanghai Hengrui Pharmaceutical Co., Ltd.54

已完成

1 期

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 1021958 in Otherwise Healthy Controlled Asthmatic SubjectsHealthyAsthma

NCT01629849Boehringer Ingelheim84